Angiopoietin-like 4 antibodies and methods of use

Patent metadata

Field	Value
Publication number	US-9771417-B2
Application number	US-201514819680-A
Country	US
Kind code	B2
Filing date	Aug 6, 2015
Priority date	Aug 7, 2014
Publication date	Sep 26, 2017
Grant date	Sep 26, 2017

Abstract

The present invention relates to monoclonal antibodies binding to human angiopoietin-like 4 protein (hereinafter, sometimes referred to as “ANGPTL4”), and pharmaceutical compositions and methods of treatment comprising the same.

First claim

The invention claimed is:

1. An isolated antibody or fragment thereof which specifically binds to human ANGPTL4, wherein said antibody or fragment comprises a heavy chain variable region comprising HCDR1 of SEQ ID NO: 7, HCDR2 of SEQ ID NO: 8, HCDR3 of SEQ ID NO: 9, and a light chain variable region comprising LCDR1 of SEQ ID NO: 17, LCDR2 of SEQ ID NO: 18, and LCDR3 of SEQ ID NO: 19.

2. A pharmaceutical composition comprising the antibody or fragment thereof of claim 1 and a pharmaceutically acceptable carrier.

3. The antibody or fragment of claim 1 , which is a monoclonal antibody, humanized antibody, single chain antibody, Fab fragment, Fv fragment, F(ab′)2 fragment, or scFv fragment.

4. The antibody or fragment of claim 3 , which is an IgG1 or IgG4 isotype.

5. The antibody or fragment of claim 1 , which comprises a light chain variable region comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 13, and a heavy chain variable region that is at least 90% identical to SEQ ID NO: 23.

6. The isolated anti-ANGPTL4 antibody or fragment thereof of claim 1 , wherein the antibody comprises a heavy chain comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 15 and a light chain comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 25.

7. The isolated anti-ANGPTL4 antibody or fragment thereof of claim 1 , wherein the antibody or fragment comprises a heavy chain comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 28 and a light chain comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 25.

8. A bispecific antibody comprising the antibody or fragment of claim 1 .

9. An isolated antibody or fragment thereof which specifically binds to human ANGPTL4, wherein said antibody or fragment further comprises a heavy chain variable region comprising HCDR1 of SEQ ID NO: 10, HCDR2 of SEQ ID NO: 11, CDR3 and HCDR3 of SEQ ID NO: 12, and a light chain variable region comprising LCDR1 of SEQ ID NO: 20, LCDR2 of SEQ ID NO: 21, and LCDR3 of SEQ ID NO: 22.

10. The antibody or fragment of claim 9 , which is a monoclonal antibody, humanized antibody, single chain antibody, Fab fragment, Fv fragment, F(ab′)2 fragment, or scFv fragment.

11. The antibody or fragment of claim 10 , which is an IgG1 or IgG4 isotype.

12. The antibody or fragment of claim 9 , which comprises a light chain variable region comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 13, and a heavy chain variable region that is at least 90% identical to SEQ ID NO: 23.

13. A bispecific antibody comprising the antibody or fragment of claim 9 .

14. A pharmaceutical composition comprising the antibody or fragment of claim 9 and a pharmaceutically acceptable carrier.

15. An isolated monoclonal anti-ANGPTL4 antibody or fragment thereof which specifically binds to human ANGPTL-4, wherein the antibody or fragment comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 13 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 23.

16. The isolated anti-ANGPTL4 antibody or fragment thereof of claim 15 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 15 and a light chain comprising the amino acid sequence of SEQ ID NO: 25.

17. A bispecific antibody comprising the antibody or fragment of claim 15 .

18. A pharmaceutical composition comprising the antibody or fragment of claim 15 and a pharmaceutically acceptable carrier.

19. An isolated monoclonal anti-ANGPTL4 antibody or fragment thereof which specifically binds to human ANGPTL-4, wherein the antibody or fragment comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 28 and a light chain comprising the amino acid sequence of SEQ ID NO: 25.

20. A pharmaceutical composition comprising the antibody or fragment of claim 19 and a pharmaceutically acceptable carrier.

Assignees

• Trauger John
• Voznesensky Andrei Igorevich
• Novartis Ag

Inventors

• Trauger John
• Voznesensky Andrei Igorevich

Classifications

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title